Amendment: SEC Form S-1/A filed by Tvardi Therapeutics Inc.
$TVRD
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/14/2025 | $5.00 | Overweight → Equal Weight | Barclays |
| 10/14/2025 | Outperform → Mkt Perform | Raymond James | |
| 10/13/2025 | Overweight → Neutral | Cantor Fitzgerald | |
| 10/13/2025 | $78.00 → $4.00 | Overweight → Neutral | Piper Sandler |
| 10/13/2025 | $61.00 | Overweight | Barclays |
| 7/14/2025 | $62.00 | Outperform | Raymond James |
| 7/11/2025 | $52.00 | Overweight | Cantor Fitzgerald |
| 6/12/2025 | $78.00 | Overweight | Piper Sandler |
Barclays downgraded Tvardi Therapeutics from Overweight to Equal Weight and set a new price target of $5.00
Raymond James downgraded Tvardi Therapeutics from Outperform to Mkt Perform
Cantor Fitzgerald downgraded Tvardi Therapeutics from Overweight to Neutral
HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that management will deliver a company presentation during the 44th Annual J.P. Morgan Healthcare Conference, being held January 12th – 15th, 2026, in San Francisco, CA. During the presentation, Tvardi will discuss and provide additional context around the new Phase 2 REVERT IPF clinical trial data for TTI-101 reported today. These new data demonstrate encouraging signals across fibrosis, inflammatory markers and pulmona
Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2.4% decrease for the placebo group Topline healthy volunteer data from Phase 1 study of next-generation STAT3 inhibitor, TTI-109, on track for H1 2026 HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today provided further updates from its Phase 2 REVERT IPF clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF). Preliminary results were announced on
Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the company's management will participate in a fireside chat and host investor one-on-one investor meetings at the Piper Sandler 37th Annual Healthcare Conference, being held December 2-4, 2025 in New York, NY. Details are as follows: Piper Sandler 37th Annual Healthcare Conference Format: Fireside Chat Date: Tuesday, December 2, 2025 Time: 12:00 PM ET The webcast of the fireside chat will be accessible on the Tvardi Investors' website. A replay of the w
8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
8-K - Tvardi Therapeutics, Inc. (0001346830) (Filer)
4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
4 - Tvardi Therapeutics, Inc. (0001346830) (Issuer)
Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ:TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today provided an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF). The REVERT IPF Phase 2 clinical trial was a randomized, double-blind, placebo-controlled clinical trial of TTI-101 alone or in addition to nintedanib (OFEV®) in patients with IPF. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory